Apotex's ruxolitinib is an oral tablet formulation intended to treat moderate to severe rheumatoid arthritis (RA) (1).

Compared to Novartis's Jakavi, a well-established competitor, Apotex's ruxolitinib is an approved generic product. The generic version provides a more affordable alternative for patients, potentially increasing access to this medication (2). According to DrugPatentWatch.com, several generic manufacturers have received FDA approval for their own versions of ruxolitinib, increasing competition in the market [3].

Apotex's ruxolitinib also differs in its patent and exclusivity status. Due to its generic status, Apotex's product does not have any remaining exclusive marketing rights, unlike its competitors, which are protected by patents (DrugPatentWatch.com).

Sources:

1. Apotex – Ruxolitinib (https://www.apotex.com/ruxolitinib-oral-tablet-20mg-25mg/)
2. Novartis – Jakavi (https://www.novartis.com/cancer/jakavi)
3. DrugPatentWatch.com - Ruxolitinib patent information (https://www.drugpatentwatch.com/drug/1403/ruxolitinib)